Tenderwize
Retour à la recherche

Open-house drug rebate agreements Berlin

AOK Nordost - Die Gesundheitskasse·Potsdam, Germany·Deadline Feb 21, 2027 · 179 days left·Open·Supplies
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Arzneimittelrabattverträge gemäß § 130a Abs. 8c SGB V für die KV-Region Berlin

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

30 / 100

Facteurs de risque

Open-House model may be superseded by regular discount contracts, leading to automatic termination of existing agreemen...

No guarantee of sales volume; contracts are non-exclusive and volume depends on prescribing behavior.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 3 lots
  • Duration until Apr 2027
  • Conclusion of non-exclusive discount agreements for oncology medications under §130a Abs. 8c SGB V
  • Medications: Bevacizumab, Rituximab, Trastuzumab (parenteral preparations from finished drugs)
Afficher le résumé complet

Open-House procedure for non-exclusive discount agreements for oncology drugs (Bevacizumab, Rituximab, Trastuzumab) in Berlin. Eligible pharmaceutical companies can join at any time until 21.02.2027. Contracts run from 01.05.2026 to 30.04.2027. No estimated value provided. No competition-based award; all eligible participants are accepted.

Risques

Open-House model may be superseded by regular discount contracts, leading to automatic termination of existing agreemen...

No guarantee of sales volume; contracts are non-exclusive and volume depends on prescribing behavior.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Current commercial register excerpt (not older than 2 years) or power of attorney

Eligibility

  • Only pharmaceutical companies (pharmazeutische Unternehmen) are eligible

Administrative

  • Suitability proof via a signed self-declaration of reliability

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Potsdam, DEU

Site web

www.aok.de

Identifiant

DE275390265

Activité

Health

Lots (3)

LOT-0001

Bevacizumab (ATC: L01FG01)

Non-exclusive discount agreement for Bevacizumab parenteral preparations for oncology use in Berlin. Open-House model, all eligible pharmaceutical companies can join.

SuppliesEU fundedElectronic submission

Localisation

Germany

Durée

Apr 2026 - Apr 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Feb 21, 2027

LOT-0002

Rituximab (ATC: L01FA01)

Non-exclusive discount agreement for Rituximab parenteral preparations for oncology use in Berlin. Open-House model, all eligible pharmaceutical companies can join.

SuppliesEU fundedElectronic submission

Localisation

Germany

Durée

Apr 2026 - Apr 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Feb 21, 2027

LOT-0003

Trastuzumab (ATC: L01FD01)

Non-exclusive discount agreement for Trastuzumab parenteral preparations for oncology use in Berlin. Open-House model, all eligible pharmaceutical companies can join.

SuppliesEU fundedElectronic submission

Localisation

Germany

Durée

Apr 2026 - Apr 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Feb 21, 2027

Détails de la procédure

Date de publication
11 Feb 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
103459-2026

Documents (2)

Appels d'offres similaires